Fulgent Genetics Inc Receivables Turnover Ratio (FLGT), from the third quarter 2026 to the third quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Fulgent Genetics Inc   (NASDAQ: FLGT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Fulgent Genetics Inc Accounts Receivables Turnover Ratio from the third quarter 2026 to the third quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Fulgent Genetics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 4.64, above the company average. This is a clear sign of healthy business climate in the Medical Laboratories industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Fulgent Genetics Inc in Sep 30 2026 quarter, has decreased to 79 days, compared to 82 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 395 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2026 from 2682 to 2719.

What is Receivable Turnover Ratio?
What is Fulgent Genetics Inc Selling?


What is Receivable Turnover Ratio?





FLGT Receivables Turnover Ratio (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Receivable Change -10.38 % -13.98 % -3.08 % 22.81 % 24.2 %
Y / Y Revenue Change 8.26 % 4.86 % -3.89 % 7.36 % 18 %
Receivable Turnover Ratio (TTM) 4.64 4.43 4.22 4.23 4.38
FLGT's Total Ranking # 2719 # 2682 # 2021 # 2527 #
Accounts Receivable average collection period days 79 82 87 86 83
Seq. Receivable Change -3.91 % -4.16 % -18.27 % 19.07 % -7.78 %
Seq. Revenue Change 5.88 % 21.14 % -15.66 % 0.08 % 2.55 %


Receivable Turnover Company Ranking
Within: No.
Medical Laboratories Industry # 24
Healthcare Sector # 396
Overall Market # 2719

Receivable Turnover Ratio Statistics
High Average Low
1.51 0.5 0.21
(Mar 31 2021)   (Sep 30 2023)






Financial Statements
Fulgent Genetics Inc 's Accounts Receivable $ 64 Millions Visit FLGT's Balance sheet
Fulgent Genetics Inc 's Sales TTM $ 330 Millions Visit FLGT's Income Statement
Sources of FLGT's Revenues Visit FLGT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Laboratories Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
FLGT's Receivable Turnover Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
FLGT's Growth Rates FLGT's Roa FLGT's Inventory Turnover Ratio FLGT's Dividend Comparisons
FLGT's Profitability Ratios FLGT's Roi FLGT's Asset Turnover Ratio FLGT's Dividend Growth
FLGT's Valuation Ratios FLGT's Roe FLGT's Financial Strength Ratios FLGT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Receivable at quarter ending Sep 30 2026
Corcept Therapeutics Inc  13.44 $ 963.647  Millions$ 71.710  Millions
Chemed Corporation  12.65 $ 2,661.041  Millions$ 210.387  Millions
Caredx Inc   11.75 $ 497.396  Millions$ 42.330  Millions
Teladoc Health Inc   11.50 $ 2,468.143  Millions$ 214.604  Millions
Biodesix Inc   11.45 $ 105.212  Millions$ 9.192  Millions
Icu Medical Inc  11.32 $ 2,183.556  Millions$ 192.845  Millions
Mannkind Corporation  10.97 $ 413.370  Millions$ 37.686  Millions
Iqvia Holdings Inc   10.43 $ 17,311.000  Millions$ 1,659.500  Millions
Voyager Therapeutics Inc   9.84 $ 25.108  Millions$ 2.551  Millions
Encompass Health Corporation  9.41 $ 6,338.100  Millions$ 673.625  Millions
Bausch Health Companies Inc   9.15 $ 11,113.000  Millions$ 1,215.000  Millions
Pacs Group Inc   8.88 $ 5,705.049  Millions$ 642.729  Millions
Lexicon Pharmaceuticals Inc   8.77 $ 38.537  Millions$ 4.396  Millions
Axogen inc   8.71 $ 266.926  Millions$ 30.654  Millions
Avita Medical Inc   8.65 $ 84.683  Millions$ 9.795  Millions
Ensign Group Inc  8.62 $ 5,674.305  Millions$ 658.477  Millions
Pediatrix Medical Group Inc   8.57 $ 1,959.124  Millions$ 228.471  Millions
Tenet Healthcare Corp  8.54 $ 22,154.000  Millions$ 2,593.250  Millions
Brightspring Health Services Inc   8.50 $ 9,479.144  Millions$ 1,114.763  Millions
Sotera Health Company  8.49 $ 1,230.250  Millions$ 144.974  Millions
Acadia Pharmaceuticals Inc   8.46 $ 1,202.301  Millions$ 142.117  Millions
Novavax inc   8.33 $ 411.649  Millions$ 49.414  Millions
Tactile Systems Technology Inc   8.23 $ 357.176  Millions$ 43.385  Millions
Penumbra Inc  8.22 $ 1,560.334  Millions$ 189.735  Millions
Inspire Medical Systems inc   8.15 $ 882.194  Millions$ 108.207  Millions
Adapthealth Corp   8.14 $ 3,152.043  Millions$ 387.280  Millions
Rhythm Pharmaceuticals Inc   8.03 $ 280.748  Millions$ 34.950  Millions
Alphatec Holdings Inc   7.91 $ 839.652  Millions$ 106.153  Millions
Exelixis Inc   7.89 $ 2,496.861  Millions$ 316.636  Millions
Henry Schein Inc   7.84 $ 13,734.000  Millions$ 1,752.000  Millions

Date modified: 2026-11-08T19:22:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.